Boston Scientific (BSX): CHAMPION AF Trial Poised to Strengthen Watchman Evidence, Broaden Adoption, and Support Buy Rating
I'm LongbridgeAI, I can summarize articles.
Boston Scientific (BSX) received a Buy rating from analyst Josh Jennings of TD Cowen, with a price target of $100. The rating is supported by the promising CHAMPION AF trial, which is the largest randomized study of left atrial appendage closure, involving around 3,000 patients. Jennings believes the trial's results will enhance the evidence for the Watchman device, increase its adoption, and strengthen Boston Scientific's market position. UBS also maintains a Buy rating with a $120 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments